Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.

Chahine LM, Siderowf A, Barnes J, Seedorff N, Caspell-Garcia C, Simuni T, Coffey CS, Galasko D, Mollenhauer B, Arnedo V, Daegele N, Frasier M, Tanner C, Kieburtz K, Marek K; The Parkinson’s Progression Markers Initiative.

J Parkinsons Dis. 2019 Aug 21. doi: 10.3233/JPD-181518. [Epub ahead of print]

PMID:
31450510
2.

Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.

Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, Simuni T, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Marek K, Galasko D; PPMI study.

Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27806. [Epub ahead of print]

PMID:
31361367
3.

Silicone optical elements for cost-effective freeform solar concentration.

Cui S, Lyons NP, Diaz LR, Ketchum R, Kim KJ, Yuan HC, Frasier M, Pan W, Norwood RA.

Opt Express. 2019 Apr 15;27(8):A572-A580. doi: 10.1364/OE.27.00A572.

PMID:
31053029
4.

Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Frank S, Jennings D, Simuni T; Parkinson's Progression Markers InitiativeSteering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board.

Parkinsonism Relat Disord. 2019 May;62:201-209. doi: 10.1016/j.parkreldis.2018.12.025. Epub 2019 Jan 31.

PMID:
30738748
5.

The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.

Marek K, Chowdhury S, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Simuni T, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun-Turgut D, Poston K, Arnedo V, Frasier M, Sherer T; Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol. 2018 Oct 31;5(12):1460-1477. doi: 10.1002/acn3.644. eCollection 2018 Dec.

6.

Finding useful biomarkers for Parkinson's disease.

Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaam6003. doi: 10.1126/scitranslmed.aam6003. Review.

7.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.

Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*.

Mov Disord. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23.

8.

Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.

Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, Taylor P, Xie T, Tuite P, Henchcliffe C, Hogarth P, Frank S, Saint-Hilaire MH, Frasier M, Arnedo V, Reimer AN, Sutherland M, Swanson-Fischer C, Gwinn K; Fox Investigation of New Biomarker Discovery, Kang UJ.

Mov Disord. 2018 Feb;33(2):282-288. doi: 10.1002/mds.27232. Epub 2017 Dec 4.

9.

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.

Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Frasier M, Marek K, Galasko D; Parkinson's Progression Marker Initiative.

Neurology. 2017 Nov 7;89(19):1959-1969. doi: 10.1212/WNL.0000000000004609. Epub 2017 Oct 13.

10.

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.

Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, Taylor P, Mollenhauer B, Schlossmacher MG, Ereshefsky L, Yen M, Kopil C, Frasier M, Marek K, Hertzberg VS, Tansey MG.

J Neuroinflammation. 2017 Aug 18;14(1):164. doi: 10.1186/s12974-017-0935-1.

11.

A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.

Mollenhauer B, Batrla R, El-Agnaf O, Galasko DR, Lashuel HA, Merchant KM, Shaw LM, Selkoe DJ, Umek R, Vanderstichele H, Zetterberg H, Zhang J, Caspell-Garcia C, Coffey C, Hutten SJ, Frasier M, Taylor P; Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research.

Mov Disord. 2017 Aug;32(8):1117-1130. doi: 10.1002/mds.27090. Epub 2017 Jul 22. Review.

12.

Interview with Mark Frasier: a Michael J Fox Foundation perspective on precision medicine in Parkinson's.

Frasier MA.

Per Med. 2017 Jan;14(1):13-15. doi: 10.2217/pme-2016-0087. Epub 2016 Nov 30.

13.

Perspective: Data sharing for discovery.

Frasier M.

Nature. 2016 Oct 27;538(7626):S4. doi: 10.1038/538S4a. No abstract available.

PMID:
27783581
14.

Parkinson's disease is ready for precision medicine.

Sherer TB, Frasier MA, Langston JW, Fiske BK.

Per Med. 2016 Sep;13(5):405-407. doi: 10.2217/pme-2016-0052. Epub 2016 Aug 9. No abstract available.

15.

The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.

Kang UJ, Goldman JG, Alcalay RN, Xie T, Tuite P, Henchcliffe C, Hogarth P, Amara AW, Frank S, Rudolph A, Casaceli C, Andrews H, Gwinn K, Sutherland M, Kopil C, Vincent L, Frasier M.

Mov Disord. 2016 Jun;31(6):924-32. doi: 10.1002/mds.26613. Epub 2016 Apr 26.

16.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative.

Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2. Epub 2016 Mar 28.

17.

Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.

Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB; Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators.

Lancet Neurol. 2015 Oct;14(10):1002-9. doi: 10.1016/S1474-4422(15)00178-7. Epub 2015 Aug 10.

18.

Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease.

Dave KD, De Silva S, Sheth NP, Ramboz S, Beck MJ, Quang C, Switzer RC 3rd, Ahmad SO, Sunkin SM, Walker D, Cui X, Fisher DA, McCoy AM, Gamber K, Ding X, Goldberg MS, Benkovic SA, Haupt M, Baptista MA, Fiske BK, Sherer TB, Frasier MA.

Neurobiol Dis. 2014 Oct;70:190-203. doi: 10.1016/j.nbd.2014.06.009. Epub 2014 Jun 24.

19.

Parkinson's disease biomarkers: resources for discovery and validation.

Frasier M, Kang UJ.

Neuropsychopharmacology. 2014 Jan;39(1):241-2. doi: 10.1038/npp.2013.246. No abstract available.

20.

Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs.

Baptista MA, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, Varsho JS, Parker GA, Moore C, Churchill MJ, Meshul CK, Fiske BK.

PLoS One. 2013 Nov 14;8(11):e80705. doi: 10.1371/journal.pone.0080705. eCollection 2013.

21.

α-synuclein imaging: a critical need for Parkinson's disease research.

Eberling JL, Dave KD, Frasier MA.

J Parkinsons Dis. 2013;3(4):565-7. doi: 10.3233/JPD-130247.

PMID:
24192754
22.

A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research.

Baptista MA, Dave KD, Sheth NP, De Silva SN, Carlson KM, Aziz YN, Fiske BK, Sherer TB, Frasier MA.

Dis Model Mech. 2013 Nov;6(6):1316-24. doi: 10.1242/dmm.011940. Epub 2013 Sep 12.

23.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative.

JAMA Neurol. 2013 Oct;70(10):1277-87.

24.

Mineral concentrations in solid fuels from European semi-natural grasslands after hydrothermal conditioning and subsequent mechanical dehydration.

Hensgen F, Bühle L, Donnison I, Frasier M, Vale J, Corton J, Heinsoo K, Melts I, Wachendorf M.

Bioresour Technol. 2012 Aug;118:332-42. doi: 10.1016/j.biortech.2012.05.035. Epub 2012 May 18.

PMID:
22705540
25.

Development of real-time assays for impedance-based detection of microbial double-stranded DNA targets: optimization and data analysis.

Ghindilis AL, Smith MW, Messing DS, Haynes VN, Middleton GB, Schwarzkopf KR, Campbell CE, Zhan C, Ulrich B, Frasier MJ, Schuele PJ, Evans DR, Sezan I, Hartzell JW, Simon HM.

Biosens Bioelectron. 2012 May 15;35(1):87-93. doi: 10.1016/j.bios.2012.02.021. Epub 2012 Feb 19.

PMID:
22405908
26.

Structures and processes of care in ambulatory oncology settings and nurse-reported exposure to chemotherapy.

Friese CR, Himes-Ferris L, Frasier MN, McCullagh MC, Griggs JJ.

BMJ Qual Saf. 2012 Sep;21(9):753-9. doi: 10.1136/bmjqs-2011-000178. Epub 2011 Aug 16.

27.

Priorities in Parkinson's disease research.

Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E.

Nat Rev Drug Discov. 2011 May;10(5):377-93. doi: 10.1038/nrd3430. Review.

PMID:
21532567
28.

Biomarkers in Parkinson's disease: a funder's perspective.

Frasier M, Chowdhury S, Eberling J, Sherer T.

Biomark Med. 2010 Oct;4(5):723-9. doi: 10.2217/bmm.10.89.

PMID:
20945984
29.

Funding of Parkinson research from industry and US federal and foundation sources.

Dorsey ER, Thompson JP, Frasier M, Sherer T, Fiske B, Nicholson S, Johnston SC, Holloway RG, Moses H 3rd.

Mov Disord. 2009 Apr 15;24(5):731-7. doi: 10.1002/mds.22446.

PMID:
19133662
30.

Special focus section: gene therapy for Parkinson's disease.

Fiske BK, Frasier MA, Sherer TB.

Exp Neurol. 2008 Jan;209(1):28-9. Epub 2007 Sep 18. No abstract available.

PMID:
17980867
31.

Fluoxetine treatment of prepubescent rats produces a selective functional reduction in the 5-HT2A receptor-mediated stimulation of oxytocin.

Landry M, Frasier M, Chen Z, Van De Kar LD, Zhang Y, Garcia F, Battaglia G.

Synapse. 2005 Nov;58(2):102-9.

PMID:
16088947
32.

Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.

Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA.

Neurobiol Dis. 2005 Apr;18(3):492-8.

PMID:
15755676
33.

Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein.

Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, Haas C, Kahle P, Wolozin B.

Exp Neurol. 2005 Apr;192(2):274-87.

PMID:
15755545
34.

Following the leader: fibrillization of alpha-synuclein and tau.

Frasier M, Wolozin B.

Exp Neurol. 2004 Jun;187(2):235-9. Review. No abstract available.

PMID:
15144849
35.

Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein.

Golts N, Snyder H, Frasier M, Theisler C, Choi P, Wolozin B.

J Biol Chem. 2002 May 3;277(18):16116-23. Epub 2002 Feb 15.

36.

The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer.

Kelley JR, Brown JM, Frasier MM, Baron PL, Schweinfest CW, Vournakis JN, Watson DK, Cole DJ.

Surgery. 2000 Aug;128(2):353-60.

PMID:
10923016
37.

Rethinking the issues regarding the culturally disadvantaged gifted.

Frasier MM.

Except Child. 1979 Apr;45(7):538-42. No abstract available.

PMID:
436888
38.

Characterization of developing antler cartilage matrix. I. Selected histochemical and enzymatic assessment.

Frasier MB, Banks WJ, Newbrey JW.

Calcif Tissue Res. 1975 Jun 18;17(4):273-88.

PMID:
125143

Supplemental Content

Loading ...
Support Center